FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL GREGORIO MARANON

Their core work

FIBHGM is the biomedical research foundation of Hospital Gregorio Marañón, one of Madrid's largest public teaching hospitals. They conduct translational clinical research spanning cardiovascular disease, immunotherapy, and neuroscience — bridging hospital-based patient access with laboratory investigation. Their work focuses on understanding disease mechanisms (cardiac, oncological, autoimmune) and translating findings into diagnostic tools and therapies, with particular strength in cardiology and cell-based treatments.

What they specialise in

How they've shifted over time

FIBHGM's early H2020 work (2019–2020) centered on cardiovascular disease mechanisms — diabetic cardiomyopathy, atrial fibrillation classification, and systems biology approaches to heart failure. From 2021 onward, their portfolio diversified significantly: they moved into cardio-oncology (protecting cancer patients' hearts), immunotherapy (Treg cell therapy for transplant rejection), and maternal neuroscience. This shift suggests the foundation is expanding from a pure cardiology focus toward cross-disciplinary clinical research that connects cardiology with oncology, immunology, and neuroscience.

FIBHGM is moving from disease-specific cardiology research toward translational clinical work at the intersection of cardiology, oncology, and immunology — expect future projects in cell therapy and cardio-oncology.

How they like to work

FIBHGM primarily joins consortia as a third party or participant rather than leading them — they coordinated only 1 of 5 projects (Allo-THYTECH, a smaller MSCA fellowship). This suggests they contribute specialized clinical expertise and patient cohort access rather than driving consortium strategy. With 57 unique partners across 12 countries, they are well-connected but operate as a specialist contributor embedded in larger research networks.

FIBHGM has collaborated with 57 unique partners across 12 countries, indicating a broad European network despite their modest project count. Their connections span RIA consortia, ERC teams, and MSCA networks, giving them reach across both large collaborative and individual excellence programmes.

What sets them apart

FIBHGM offers something rare: direct access to a major hospital's clinical infrastructure combined with research foundation agility. Their cardio-oncology and Treg cell therapy work sits at therapeutic frontiers where few hospital-based foundations operate in H2020. For consortium builders, they bring clinical trial capacity, patient cohorts, and the ability to translate bench research into bedside application within a single institution.

Highlights from their portfolio

• Allo-THYTECH
  Their only coordinated project, developing allogeneic Treg cell therapy — an advanced therapy at the intersection of immunology, transplantation, and autoimmune disease including COVID-19 applications.
• BEMOTHER
  Largest funded project (EUR 522,531), studying an unusual topic for a hospital foundation: neuroplasticity and brain adaptation during pregnancy and motherhood.
• RESILIENCE
  Addresses the growing cardio-oncology field — protecting lymphoma patients' hearts during chemotherapy — a clinically urgent problem with significant commercial potential.